RT Conference Proceedings
T1 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)
A1 Albanell, J.
A1 Martinez, M. T. M.
A1 Ramos, M.
A1 O'Connor, M.
A1 De la Cruz-Merino, L.
A1 Santaballa Bertran, A.
A1 Martinez-Janez, N.
A1 Moreno, F.
A1 Fernandez Perez, I.
A1 Alarcon Company, J.
A1 Virizuela Echaburu, J. A.
A1 De la Haba Rodriguez, J.
A1 Sanchez-Rovira, P.
A1 Gonzalez-Cortijo, L.
A1 Margeli Vila, M.
A1 Sanchez Munoz, A.
A1 Garau Llinas, I.
A1 Casas, M.
A1 Bezares Montes, S.
A1 Rojo Todo, F.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/25918
UL https://hdl.handle.net/10668/25918
LA en
DS RISalud
RD Apr 11, 2025